Alfentanil

Overview

Alfentanil (Alfenta®) is a potent, short-acting synthetic opioid agonist belonging to the phenylpiperidine class, closely related to fentanyl. In veterinary medicine, it is used primarily as an adjunctive anesthetic and analgesic agent in dogs and cats, particularly in controlled anesthetic settings requiring rapid onset and precise titration.

Alfentanil is characterized by a very rapid onset of action (within 15-30 seconds of IV administration) and a relatively short duration of action . These properties make it suitable for intraoperative analgesia, anesthetic supplementation, and use as part of balanced anesthesia protocols. It does not provide long-lasting postoperative analgesia when used alone.

Mechanism of Action (MOA): Alfentanil is a potent µ-opioid receptor agonist. Activation of central opioid receptors results in analgesia, sedation, and dose-dependent respiratory depression. Like other opioids, it reduces anesthetic requirements at least a 50% dose reduction of co-administered anesthetics including inhalant agents. In cats, plasma alfentanil concentrations of 500 ng/mL decreased isoflurane MAC by 16-35%.

Due to its high potency and narrow margin between analgesic and respiratory-depressant effects, alfentanil should only be used in environments where advanced monitoring, airway control, and ventilatory support are readily available. Veterinary clinical experience is limited compared with more commonly used opioids, and careful dose calculation and patient selection are essential.

Indications

Alfentanil is used in veterinary medicine primarily as a potent opioid adjunct for anesthesia and analgesia in dogs and cats. Its rapid onset and short duration of action make it most suitable for controlled anesthetic settings where close monitoring and titration to effect are possible.

• Adjunct to general anesthesia: Used to supplement injectable or inhalant anesthetic protocols in dogs and cats, allowing dose reduction of agents such as propofol or inhalant anesthetics.
• Intraoperative analgesia: Administered as IV boluses or continuous rate infusions (CRI) to provide analgesia during surgical procedures, particularly when rapid onset and fine dose control are desired.
• Balanced anesthesia protocols: Combined with agents such as propofol, or inhalant anesthetics to enhance anesthetic depth and stability while minimizing individual drug doses.
• Analgesic support in high-risk patients: May be considered as an alternative to fentanyl in select dogs and cats, including patients in which short-acting opioids are preferred; however, careful monitoring is essential due to respiratory and cardiovascular effects.
• Intracranial disease (dogs): Used as an intraoperative analgesic CRI at low doses to provide analgesia with controlled anesthetic depth in patients undergoing procedures involving intracranial pathology.

Alfentanil is not indicated for use as a sole anesthetic agent and does not provide adequate sedation or anesthesia when used alone. Its use should be limited to facilities with the capability for advanced monitoring, airway management, and ventilatory support.

Dosage (Reference)

Alfentanil is a highly potent opioid, and dosing must be precise and titrated to effect. Because of its short duration of action, it is most commonly administered as IV boluses or continuous rate infusions (CRI) in monitored anesthetic settings. In obese patients, doses should be calculated based on lean body weight.

Dog

Cat

Warnings & Precautions

Alfentanil is a highly potent opioid agonist with a narrow margin of safety. Its use should be restricted to controlled clinical settings where advanced monitoring, airway management, and emergency support are immediately available.

• Respiratory depression: Dose-dependent respiratory depression and apnea may occur, especially after rapid IV administration or overdose. Continuous monitoring of respiratory rate, oxygenation, and ventilation is mandatory.
• Cardiovascular effects: Bradycardia has been reported in dogs and may require anticholinergic support. Hypotension or hypertension can occur depending on dose, species, and concurrent drugs. CRITICAL: rapid IV injection can cause severe bradycardia, even asystole — always administer slowly. Cats may exhibit tachycardia and increased blood pressure rather than bradycardia.
• No intrinsic anesthetic depth: Alfentanil alone does not provide adequate anesthesia; it must be used as part of a balanced anesthetic protocol.
• Head injury and neurologic disease: Use with caution in patients with head trauma or increased intracranial pressure due to potential effects on ventilation and cerebral perfusion.
• Pulmonary disease: Animals with compromised respiratory function are at increased risk for hypoventilation and hypoxemia.
• Hepatic and renal impairment: Clearance may be reduced, leading to prolonged or exaggerated effects; dose reduction and careful titration are recommended.
• Geriatric and debilitated patients: Increased sensitivity may occur . Start at the lowest effective dose and titrate slowly. Initial dose reduction may also be required in debilitated patients, particularly those with diminished cardiopulmonary function.
• Obese patients: Doses should be calculated based on lean body weight to avoid overdose.
• CNS excitation: Cats and horses may exhibit excitement, mydriasis, or increased locomotor activity, particularly after IV bolus administration.
• Scorpion envenomation: Opioids are contraindicated in animals stung by scorpions (e.g., Centruroides spp.) due to potentiation of venom effects.
• Medication errors: Do not confuse alfentanil with fentanyl, sufentanil, or remifentanil. Due to its potency, use tuberculin syringes and double-check all dose calculations.
• Controlled substance: Alfentanil is a DEA Schedule II drug and must be stored, handled, and documented according to applicable regulations.
• Pregnancy & lactation: Alfentanil crosses the placenta. Use systemically near parturition has been associated with neonatal hypotonia and depression. Prolonged high doses in laboratory animals caused embryotoxicity (teratogenicity not seen). Excreted in milk. Use only when maternal benefits outweigh potential fetal/neonatal risks.

Drug Interactions

The following drug interactions with alfentanil have been reported or are theoretical based on human and animal data. Concurrent use is not always contraindicated, but potential risks should be carefully weighed and additional monitoring implemented when appropriate.

• Anticholinergic agents: May increase the risk of urinary retention, constipation, and additive CNS and respiratory depression.
• Bethanechol: Alfentanil may antagonize the prokinetic effects of bethanechol; concurrent use is not recommended.
• Bradycardia-inducing drugs: Increased risk of clinically significant bradycardia and hypotension.
• CNS depressants: Additive or synergistic CNS and respiratory depression may occur; dose reductions and close monitoring are required.
• Desmopressin: May increase desmopressin concentrations, raising the risk of water intoxication, hyponatremia, seizures, coma, and respiratory arrest; monitor electrolytes closely.
• Diuretics: Opioids may reduce the therapeutic effectiveness of diuretics.
• Domperidone: Alfentanil may antagonize the gastrointestinal prokinetic effects.
• Hepatic enzyme inducers: May decrease alfentanil plasma concentrations; monitor clinical response and adjust dose if needed.
• Hepatic enzyme inhibitors: May decrease clearance and prolong alfentanil effects, increasing the risk of respiratory depression.
• Highly protein-bound drugs: Theoretical displacement interactions may occur, but are usually not clinically significant; monitor for adverse effects.
• Hypotensive agents: Increased risk of hypotension, bradycardia, and orthostatic effects.
• Ifosfamide: Concurrent use may increase the risk of neurotoxicity including confusion, hallucinations, seizures, and coma.
• Iohexol (intrathecal use): Opioids may increase seizure risk; withhold opioids 48 hours before and 24 hours after intrathecal iohexol administration.
• Loperamide: Increased risk of constipation due to additive opioid effects.
• MAOIs: May cause severe CNS depression, hypotension, respiratory depression, cyanosis, and coma; avoid combination and allow a 14-day washout period.
• Neuromuscular blocking agents: May increase the risk of cardiovascular instability; monitor heart rate and blood pressure closely.
• Prokinetic agents: Opioids may antagonize gastrointestinal prokinetic effects.

Side Effects & Overdose

Side Effects

Information on alfentanil adverse effects in veterinary patients is limited. Reported and expected effects are generally dose-dependent and consistent with those of other potent opioid agonists, primarily involving the cardiovascular and respiratory systems.

• Respiratory depression: Dose-dependent hypoventilation or apnea may occur in dogs, cats, and horses, particularly with rapid IV administration or high doses.
• Cardiovascular effects: Bradycardia has been reported in dogs and is usually responsive to anticholinergic agents, though atropine may increase the risk of hypotension. Cats may exhibit tachycardia or hypertension.
• CNS effects: Sedation is expected; however, cats and horses may exhibit excitation, agitation, mydriasis, increased locomotor activity, or vocalization following IV administration.
• Blood pressure changes: Hypotension or hypertension may occur depending on species, dose, and concurrent anesthetic agents.
• Muscle rigidity: Dose-related skeletal muscle rigidity has been reported in humans and may occur in veterinary patients, particularly during anesthesia.
• Gastrointestinal effects: Nausea and vomiting are possible but poorly documented in veterinary species.
• Rare reactions: Hypersensitivity reactions and severe cardiovascular instability have been rarely reported.

Overdose

Overdose with alfentanil can result in life-threatening CNS and respiratory depression. Severity depends on dose, rate of administration, and concurrent drug use.

• Mild to moderate overdose: CNS depression, respiratory depression, hypotension, bradycardia, muscle flaccidity, miosis, coma, and hypothermia.
• Severe overdose: Pulmonary edema, seizures, circulatory collapse, cardiac arrest, and death.
• Species-specific observations: IV doses as low as 30 µg/kg have caused agitation and incoordination in dogs. The reported LD50 in dogs is approximately 60-88 mg/kg IV.
• Management: Immediate supportive care including airway management, oxygen supplementation, ventilation support, and cardiovascular monitoring.
• Opioid reversal: Naloxone may be administered to reverse opioid effects; repeat dosing may be necessary due to alfentanil’s shorter half-life.
• Monitoring: Extended observation may be required due to the risk of recurrent respiratory depression.

Key Notes

Practical clinical considerations for the use of alfentanil in dogs and cats, focusing on points that influence case selection, dosing strategy, and clinical handling.

• Short-acting opioid: Alfentanil has a rapid onset and relatively short duration of action compared with other opioids, making it useful for titratable intraoperative analgesia and brief procedures.
• Primarily an anesthetic adjunct: Most commonly used as part of a balanced anesthesia protocol rather than as a sole agent, especially when rapid adjustments in anesthetic depth are required.
• Lean body weight dosing: In obese patients, doses should be calculated based on lean body weight to reduce the risk of overdose and prolonged effects.
• CRI-friendly opioid: Well suited for use as a continuous rate infusion (CRI) to maintain stable plasma concentrations during anesthesia.
• Species variability: Clinical response varies between dogs and cats, with cats more likely to show CNS stimulation rather than pure sedation.
• High-potency handling: Due to its potency, accurate dose calculation, dilution, and use of small-volume syringes are essential to avoid dosing errors.
• Controlled substance considerations: As a DEA Schedule II drug, alfentanil requires strict storage, documentation, and inventory control in clinical settings.
• Recovery quality: Smooth recovery is optimized when alfentanil is combined with appropriate sedatives and environmental stimulation is minimized during emergence.